OA11453A - Methods for treatment of diabetes using peptide analogues of insulin. - Google Patents
Methods for treatment of diabetes using peptide analogues of insulin. Download PDFInfo
- Publication number
- OA11453A OA11453A OA1200000229A OA1200000229A OA11453A OA 11453 A OA11453 A OA 11453A OA 1200000229 A OA1200000229 A OA 1200000229A OA 1200000229 A OA1200000229 A OA 1200000229A OA 11453 A OA11453 A OA 11453A
- Authority
- OA
- OAPI
- Prior art keywords
- peptide
- chain
- insulin
- cells
- nbi
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 195
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 58
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 26
- 238000011282 treatment Methods 0.000 title claims description 25
- 238000000034 method Methods 0.000 title claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 17
- 238000011161 development Methods 0.000 claims abstract 7
- 230000002401 inhibitory effect Effects 0.000 claims abstract 3
- 108090001061 Insulin Proteins 0.000 claims description 71
- 102000004877 Insulin Human genes 0.000 claims description 69
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 62
- 210000004027 cell Anatomy 0.000 claims description 38
- 238000006467 substitution reaction Methods 0.000 claims description 30
- 229940125396 insulin Drugs 0.000 claims description 24
- 235000001014 amino acid Nutrition 0.000 claims description 23
- 150000001413 amino acids Chemical class 0.000 claims description 18
- 101500025354 Homo sapiens Insulin B chain Proteins 0.000 claims description 17
- 235000004279 alanine Nutrition 0.000 claims description 17
- 239000000427 antigen Substances 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 7
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 230000008901 benefit Effects 0.000 claims description 3
- 108010044226 Class 8 Receptor-Like Protein Tyrosine Phosphatases Proteins 0.000 claims description 2
- 102000006449 Class 8 Receptor-Like Protein Tyrosine Phosphatases Human genes 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 102000054766 genetic haplotypes Human genes 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 210000004153 islets of langerhan Anatomy 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 claims 48
- 108010083255 NBI6024 Proteins 0.000 claims 48
- PHEWVCZHSBTZFX-DBCSJUPNSA-N (4s)-4-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]pro Chemical compound NC(N)=NCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CC1=CN=CN1 PHEWVCZHSBTZFX-DBCSJUPNSA-N 0.000 claims 46
- 230000004044 response Effects 0.000 claims 39
- 229940024606 amino acid Drugs 0.000 claims 18
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 17
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims 13
- 210000001165 lymph node Anatomy 0.000 claims 13
- 241000699666 Mus <mouse, genus> Species 0.000 claims 11
- 239000002609 medium Substances 0.000 claims 11
- 210000004369 blood Anatomy 0.000 claims 10
- 239000008280 blood Substances 0.000 claims 10
- 229920005989 resin Polymers 0.000 claims 10
- 239000011347 resin Substances 0.000 claims 10
- 238000003556 assay Methods 0.000 claims 9
- 230000003053 immunization Effects 0.000 claims 9
- 230000000638 stimulation Effects 0.000 claims 9
- 230000003442 weekly effect Effects 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims 8
- 210000004698 lymphocyte Anatomy 0.000 claims 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 8
- -1 2-chlorobenzyloxycarbonyl Chemical group 0.000 claims 7
- 102000004127 Cytokines Human genes 0.000 claims 7
- 108090000695 Cytokines Proteins 0.000 claims 7
- 230000004075 alteration Effects 0.000 claims 7
- 230000005847 immunogenicity Effects 0.000 claims 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 6
- 241000282414 Homo sapiens Species 0.000 claims 6
- 101800001814 Neurotensin Proteins 0.000 claims 6
- 238000000338 in vitro Methods 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 210000004989 spleen cell Anatomy 0.000 claims 6
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims 5
- 102400001103 Neurotensin Human genes 0.000 claims 5
- 239000002671 adjuvant Substances 0.000 claims 5
- 230000005764 inhibitory process Effects 0.000 claims 5
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 claims 5
- 229940104230 thymidine Drugs 0.000 claims 5
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims 4
- 108700031361 Brachyury Proteins 0.000 claims 4
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 4
- 230000002829 reductive effect Effects 0.000 claims 4
- 238000003786 synthesis reaction Methods 0.000 claims 4
- 238000012360 testing method Methods 0.000 claims 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims 3
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims 3
- 102000004388 Interleukin-4 Human genes 0.000 claims 3
- 108090000978 Interleukin-4 Proteins 0.000 claims 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-Tyrosine Natural products OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 3
- 150000008575 L-amino acids Chemical group 0.000 claims 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 3
- 239000004472 Lysine Substances 0.000 claims 3
- 229930195725 Mannitol Natural products 0.000 claims 3
- 241001529936 Murinae Species 0.000 claims 3
- 108010005991 Pork Regular Insulin Proteins 0.000 claims 3
- 230000008878 coupling Effects 0.000 claims 3
- 238000010168 coupling process Methods 0.000 claims 3
- 238000005859 coupling reaction Methods 0.000 claims 3
- 238000004128 high performance liquid chromatography Methods 0.000 claims 3
- 238000002649 immunization Methods 0.000 claims 3
- 230000002163 immunogen Effects 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 3
- 239000000594 mannitol Substances 0.000 claims 3
- 235000010355 mannitol Nutrition 0.000 claims 3
- 230000001717 pathogenic effect Effects 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 235000018102 proteins Nutrition 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 230000002285 radioactive effect Effects 0.000 claims 3
- 229960004441 tyrosine Drugs 0.000 claims 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 2
- UHPQFNXOFFPHJW-UHFFFAOYSA-N (4-methylphenyl)-phenylmethanamine Chemical compound C1=CC(C)=CC=C1C(N)C1=CC=CC=C1 UHPQFNXOFFPHJW-UHFFFAOYSA-N 0.000 claims 2
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 claims 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 2
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 claims 2
- HBAHZZVIEFRTEY-UHFFFAOYSA-N 2-heptylcyclohex-2-en-1-one Chemical compound CCCCCCCC1=CCCCC1=O HBAHZZVIEFRTEY-UHFFFAOYSA-N 0.000 claims 2
- 108700028369 Alleles Proteins 0.000 claims 2
- 229940122450 Altered peptide ligand Drugs 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 102000000743 Interleukin-5 Human genes 0.000 claims 2
- 108010002616 Interleukin-5 Proteins 0.000 claims 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 2
- 229920001367 Merrifield resin Polymers 0.000 claims 2
- 102000047918 Myelin Basic Human genes 0.000 claims 2
- 101710107068 Myelin basic protein Proteins 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 2
- 239000004473 Threonine Substances 0.000 claims 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 2
- 230000010933 acylation Effects 0.000 claims 2
- 238000005917 acylation reaction Methods 0.000 claims 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 claims 2
- 230000008485 antagonism Effects 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 108010016616 cysteinylglycine Proteins 0.000 claims 2
- 229960004132 diethyl ether Drugs 0.000 claims 2
- 238000010790 dilution Methods 0.000 claims 2
- 239000012895 dilution Substances 0.000 claims 2
- 238000002474 experimental method Methods 0.000 claims 2
- 239000012847 fine chemical Substances 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 238000010348 incorporation Methods 0.000 claims 2
- 238000011534 incubation Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 210000000265 leukocyte Anatomy 0.000 claims 2
- 230000007774 longterm Effects 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- QPJSUIGXIBEQAC-UHFFFAOYSA-N n-(2,4-dichloro-5-propan-2-yloxyphenyl)acetamide Chemical compound CC(C)OC1=CC(NC(C)=O)=C(Cl)C=C1Cl QPJSUIGXIBEQAC-UHFFFAOYSA-N 0.000 claims 2
- 238000004810 partition chromatography Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000012071 phase Substances 0.000 claims 2
- 239000000047 product Substances 0.000 claims 2
- 238000000746 purification Methods 0.000 claims 2
- 239000007790 solid phase Substances 0.000 claims 2
- 210000000952 spleen Anatomy 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 230000002459 sustained effect Effects 0.000 claims 2
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 2
- GPYTYOMSQHBYTK-LURJTMIESA-N (2s)-2-azaniumyl-2,3-dimethylbutanoate Chemical compound CC(C)[C@](C)([NH3+])C([O-])=O GPYTYOMSQHBYTK-LURJTMIESA-N 0.000 claims 1
- FAAHJOLJYDXKKU-ZHDGNLTBSA-N (2s)-6-amino-2-[[(2s)-1-[(2s,3r)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]hexanoic acid Chemical compound C([C@@H](C(=O)N[C@@H]([C@H](O)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CN)C1=CC=C(O)C=C1 FAAHJOLJYDXKKU-ZHDGNLTBSA-N 0.000 claims 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 claims 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 claims 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 108010075254 C-Peptide Proteins 0.000 claims 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 241000134884 Ericales Species 0.000 claims 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims 1
- 108010024636 Glutathione Proteins 0.000 claims 1
- DHDOADIPGZTAHT-YUMQZZPRSA-N Gly-Glu-Arg Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DHDOADIPGZTAHT-YUMQZZPRSA-N 0.000 claims 1
- MKIAPEZXQDILRR-YUMQZZPRSA-N Gly-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)CN MKIAPEZXQDILRR-YUMQZZPRSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- LJUIEESLIAZSFR-SRVKXCTJSA-N His-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N LJUIEESLIAZSFR-SRVKXCTJSA-N 0.000 claims 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims 1
- 101000591210 Homo sapiens Receptor-type tyrosine-protein phosphatase-like N Proteins 0.000 claims 1
- 108090000144 Human Proteins Proteins 0.000 claims 1
- 102000003839 Human Proteins Human genes 0.000 claims 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 claims 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-Valine Natural products CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- 229930195714 L-glutamate Natural products 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L L-glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 claims 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims 1
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 claims 1
- JGKHAFUAPZCCDU-BZSNNMDCSA-N Leu-Tyr-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CC=C(O)C=C1 JGKHAFUAPZCCDU-BZSNNMDCSA-N 0.000 claims 1
- TUIOUEWKFFVNLH-DCAQKATOSA-N Leu-Val-Cys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(O)=O TUIOUEWKFFVNLH-DCAQKATOSA-N 0.000 claims 1
- AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 claims 1
- 102000008072 Lymphokines Human genes 0.000 claims 1
- 108010074338 Lymphokines Proteins 0.000 claims 1
- GOUWCZRDTWTODO-YDHLFZDLSA-N Phe-Val-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O GOUWCZRDTWTODO-YDHLFZDLSA-N 0.000 claims 1
- 241000700159 Rattus Species 0.000 claims 1
- 102100034091 Receptor-type tyrosine-protein phosphatase-like N Human genes 0.000 claims 1
- 229920005654 Sephadex Polymers 0.000 claims 1
- 239000012507 Sephadex™ Substances 0.000 claims 1
- CICQXRWZNVXFCU-SRVKXCTJSA-N Ser-His-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O CICQXRWZNVXFCU-SRVKXCTJSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 230000024932 T cell mediated immunity Effects 0.000 claims 1
- 102000004142 Trypsin Human genes 0.000 claims 1
- 108090000631 Trypsin Proteins 0.000 claims 1
- FPCIBLUVDNXPJO-XPUUQOCRSA-N Val-Cys-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CS)C(=O)NCC(O)=O FPCIBLUVDNXPJO-XPUUQOCRSA-N 0.000 claims 1
- XGJLNBNZNMVJRS-NRPADANISA-N Val-Glu-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O XGJLNBNZNMVJRS-NRPADANISA-N 0.000 claims 1
- 239000008351 acetate buffer Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 150000001294 alanine derivatives Chemical class 0.000 claims 1
- 150000003973 alkyl amines Chemical class 0.000 claims 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- 230000009435 amidation Effects 0.000 claims 1
- 238000007112 amidation reaction Methods 0.000 claims 1
- 150000001408 amides Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 229940000635 beta-alanine Drugs 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000007975 buffered saline Substances 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 239000001569 carbon dioxide Substances 0.000 claims 1
- 229910002092 carbon dioxide Inorganic materials 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 238000005277 cation exchange chromatography Methods 0.000 claims 1
- 239000006285 cell suspension Substances 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 238000001311 chemical methods and process Methods 0.000 claims 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 claims 1
- 239000012043 crude product Substances 0.000 claims 1
- 230000016396 cytokine production Effects 0.000 claims 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 claims 1
- XYWDPYKBIRQXQS-UHFFFAOYSA-N di-isopropyl sulphide Natural products CC(C)SC(C)C XYWDPYKBIRQXQS-UHFFFAOYSA-N 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000010432 diamond Substances 0.000 claims 1
- 230000029087 digestion Effects 0.000 claims 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims 1
- 231100000673 dose–response relationship Toxicity 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- KSCFJBIXMNOVSH-UHFFFAOYSA-N dyphylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)CO)C=N2 KSCFJBIXMNOVSH-UHFFFAOYSA-N 0.000 claims 1
- 238000005516 engineering process Methods 0.000 claims 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 claims 1
- 239000011152 fibreglass Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000002523 gelfiltration Methods 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 108010049041 glutamylalanine Proteins 0.000 claims 1
- 229960003180 glutathione Drugs 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 claims 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 claims 1
- 229960002591 hydroxyproline Drugs 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 108010086646 insulin B (9-23) Proteins 0.000 claims 1
- 229940028885 interleukin-4 Drugs 0.000 claims 1
- 229940100602 interleukin-5 Drugs 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000004255 ion exchange chromatography Methods 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 230000000670 limiting effect Effects 0.000 claims 1
- 238000001325 log-rank test Methods 0.000 claims 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 claims 1
- WXEHBUMAEPOYKP-UHFFFAOYSA-N methylsulfanylethane Chemical compound CCSC WXEHBUMAEPOYKP-UHFFFAOYSA-N 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 238000006386 neutralization reaction Methods 0.000 claims 1
- 238000010647 peptide synthesis reaction Methods 0.000 claims 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims 1
- 230000002688 persistence Effects 0.000 claims 1
- 239000002953 phosphate buffered saline Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000000770 proinflammatory effect Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000000644 propagated effect Effects 0.000 claims 1
- 230000001902 propagating effect Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 230000009257 reactivity Effects 0.000 claims 1
- 238000004007 reversed phase HPLC Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 238000005063 solubilization Methods 0.000 claims 1
- 230000007928 solubilization Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 239000012588 trypsin Substances 0.000 claims 1
- 229960004295 valine Drugs 0.000 claims 1
- 230000006378 damage Effects 0.000 description 2
- 101150014889 Gad1 gene Proteins 0.000 description 1
- 102100035902 Glutamate decarboxylase 1 Human genes 0.000 description 1
- 102100035857 Glutamate decarboxylase 2 Human genes 0.000 description 1
- 101000873786 Homo sapiens Glutamate decarboxylase 2 Proteins 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2815698A | 1998-02-23 | 1998-02-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA11453A true OA11453A (en) | 2003-12-08 |
Family
ID=21841884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA1200000229A OA11453A (en) | 1998-02-23 | 2000-08-22 | Methods for treatment of diabetes using peptide analogues of insulin. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6197926B1 (enExample) |
| EP (1) | EP1056776A1 (enExample) |
| JP (1) | JP2002504491A (enExample) |
| KR (1) | KR20010041238A (enExample) |
| CN (1) | CN1241942C (enExample) |
| AP (1) | AP2000001888A0 (enExample) |
| AU (1) | AU741037B2 (enExample) |
| BR (1) | BR9908178A (enExample) |
| CA (1) | CA2321929A1 (enExample) |
| EA (1) | EA003944B1 (enExample) |
| HU (1) | HUP0100928A3 (enExample) |
| ID (1) | ID26788A (enExample) |
| IL (1) | IL137904A0 (enExample) |
| NO (1) | NO20004198L (enExample) |
| NZ (1) | NZ506447A (enExample) |
| OA (1) | OA11453A (enExample) |
| PL (1) | PL342517A1 (enExample) |
| SK (1) | SK12412000A3 (enExample) |
| TR (1) | TR200003048T2 (enExample) |
| WO (1) | WO1999042482A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6562942B1 (en) | 1999-02-23 | 2003-05-13 | Neurocrine Biosciences, Inc. | Methods for treatment of diabetes using peptide analogues of insulin |
| CN1125081C (zh) * | 1999-09-08 | 2003-10-22 | 中国科学院上海生物化学研究所 | 重组天然和新型人胰岛素及其制备方法 |
| US7462486B2 (en) * | 2000-05-12 | 2008-12-09 | Oregon Health & Science University | Methods of selecting T cell receptor V peptides for therapeutic use |
| ATE367816T1 (de) * | 2000-05-12 | 2007-08-15 | Univ Oregon Health & Science | Verwendung von niedrigen dosen estrogen in kombination mit immunotherapeutischen verbindungen zur behandlung von immunkrankheiten |
| US20020103131A1 (en) * | 2001-01-26 | 2002-08-01 | Jacobson Jill D. | Prevention of diabetes by administration of GnRH antagonists |
| US20070172453A1 (en) * | 2002-08-30 | 2007-07-26 | Vincent Geenen | Tolerogenic approach for type 1 diabetes |
| US20040138116A1 (en) * | 2002-08-30 | 2004-07-15 | Vincent Geenen | Tolerogenic approach for type 1 diabetes |
| ZA200502613B (en) | 2002-10-10 | 2006-10-25 | Yeda Res & Dev | Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents |
| JP2006526651A (ja) * | 2003-06-02 | 2006-11-24 | マーシア・ファーマ・インコーポレイテッド | １型糖尿病の処置のための治療的ワクチン組成物 |
| US8053197B2 (en) * | 2004-07-30 | 2011-11-08 | Oregon Health & Science University | Methods for detecting and treating autoimmune disorders |
| US7833513B2 (en) | 2004-12-03 | 2010-11-16 | Rhode Island Hospital | Treatment of Alzheimer's Disease |
| DE102008003566A1 (de) * | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| AU2009203809B2 (en) | 2008-01-09 | 2013-07-25 | Sanofi-Aventis Deutschland Gmbh | Novel insulin derivatives having an extremely delayed time-action profile |
| JP2011511778A (ja) | 2008-01-30 | 2011-04-14 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | エステルに基づいたペプチドプロドラッグ |
| HUE068164T2 (hu) | 2008-10-17 | 2024-12-28 | Sanofi Aventis Deutschland | Egy inzulin és egy GLP-1 agonista kombinációja |
| US8481485B2 (en) * | 2008-12-19 | 2013-07-09 | Indiana University Research And Technology Corporation | Insulin analogs |
| AU2009335715B2 (en) | 2008-12-19 | 2016-09-15 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
| WO2011056226A1 (en) | 2009-11-05 | 2011-05-12 | Mercia Pharma Llc | Adjuvanted nanoparticulate influenza vaccine |
| SG10201500871TA (en) | 2009-11-13 | 2015-04-29 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist and methionine |
| CA2780460C (en) | 2009-11-13 | 2018-09-04 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine |
| US20110311536A1 (en) * | 2010-06-11 | 2011-12-22 | Dana-Farber Cancer Institute, Inc. | Prevention of type 1 diabetes by treg vaccination with an insulin mimetope |
| AU2011268327B2 (en) | 2010-06-16 | 2016-02-25 | Indiana University Research And Technology Corporation | Single chain insulin agonists exhibiting high activity at the insulin receptor |
| US8946147B2 (en) | 2010-06-24 | 2015-02-03 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
| RS55378B1 (sr) | 2010-08-30 | 2017-03-31 | Sanofi Aventis Deutschland | Upotreba ave0010 za proizvodnju leka za tretman diabetes mellitus tipa 2 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| UA113626C2 (xx) * | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| BR112014015156A2 (pt) | 2011-12-20 | 2020-10-27 | Indiana University Research And Technology Corporation | análogos de insulina à base de ctp, seus métodos de produção e uso no tratamento de hiperglicemia, bem como sequência de ácido nucleico e célula hospedeira |
| CN108383902A (zh) | 2012-09-26 | 2018-08-10 | 印第安纳大学研究及科技有限公司 | 胰岛素类似物二聚体 |
| WO2014158900A1 (en) | 2013-03-14 | 2014-10-02 | Indiana University Research And Technology Corporation | Insulin-incretin conjugates |
| JP6657230B2 (ja) | 2014-09-24 | 2020-03-04 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | インクレチン−インスリンコンジュゲート |
| ES2947409T3 (es) | 2014-09-24 | 2023-08-08 | Univ Indiana Res & Tech Corp | Profármacos de insulina a base de amida lipídica |
| TWI758239B (zh) | 2014-12-12 | 2022-03-21 | 德商賽諾菲阿凡提斯德意志有限公司 | 甘精胰島素/利司那肽固定比率配製劑 |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| CN111925420B (zh) * | 2019-12-11 | 2022-04-01 | 山东大学 | 一种多肽作为嗅觉受体Olfr109激动剂配体的应用 |
| USD1043348S1 (en) * | 2021-09-24 | 2024-09-24 | H.J. Heinz Company Brands Llc | Bottle |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5008241A (en) * | 1985-03-12 | 1991-04-16 | Novo Nordisk A/S | Novel insulin peptides |
| PH25772A (en) * | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| US5559094A (en) | 1994-08-02 | 1996-09-24 | Eli Lilly And Company | AspB1 insulin analogs |
| US5594100A (en) * | 1995-02-22 | 1997-01-14 | Regents Of The University Of Colorado | Epitope for prevention of type I diabetes |
| EP0835129B1 (en) * | 1995-06-30 | 2003-10-29 | Novo Nordisk A/S | Prevention of a disease having the characteristics of diabetes |
-
1999
- 1999-02-23 EP EP99908385A patent/EP1056776A1/en not_active Withdrawn
- 1999-02-23 HU HU0100928A patent/HUP0100928A3/hu unknown
- 1999-02-23 TR TR2000/03048T patent/TR200003048T2/xx unknown
- 1999-02-23 CA CA002321929A patent/CA2321929A1/en not_active Abandoned
- 1999-02-23 PL PL99342517A patent/PL342517A1/xx not_active Application Discontinuation
- 1999-02-23 AU AU27831/99A patent/AU741037B2/en not_active Ceased
- 1999-02-23 CN CNB998042765A patent/CN1241942C/zh not_active Expired - Fee Related
- 1999-02-23 IL IL13790499A patent/IL137904A0/xx unknown
- 1999-02-23 JP JP2000532434A patent/JP2002504491A/ja active Pending
- 1999-02-23 ID IDW20001917A patent/ID26788A/id unknown
- 1999-02-23 SK SK1241-2000A patent/SK12412000A3/sk unknown
- 1999-02-23 US US09/255,668 patent/US6197926B1/en not_active Expired - Fee Related
- 1999-02-23 NZ NZ506447A patent/NZ506447A/xx unknown
- 1999-02-23 AP APAP/P/2000/001888A patent/AP2000001888A0/en unknown
- 1999-02-23 EA EA200000872A patent/EA003944B1/ru not_active IP Right Cessation
- 1999-02-23 BR BR9908178-4A patent/BR9908178A/pt not_active IP Right Cessation
- 1999-02-23 KR KR1020007009330A patent/KR20010041238A/ko not_active Abandoned
- 1999-02-23 WO PCT/US1999/003915 patent/WO1999042482A1/en not_active Ceased
-
2000
- 2000-08-22 OA OA1200000229A patent/OA11453A/en unknown
- 2000-08-22 NO NO20004198A patent/NO20004198L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1241942C (zh) | 2006-02-15 |
| NO20004198L (no) | 2000-10-20 |
| NO20004198D0 (no) | 2000-08-22 |
| SK12412000A3 (sk) | 2002-05-09 |
| JP2002504491A (ja) | 2002-02-12 |
| WO1999042482A1 (en) | 1999-08-26 |
| TR200003048T2 (tr) | 2000-12-21 |
| CA2321929A1 (en) | 1999-08-26 |
| HUP0100928A3 (en) | 2001-11-28 |
| EA003944B1 (ru) | 2003-10-30 |
| EA200000872A1 (ru) | 2001-02-26 |
| IL137904A0 (en) | 2001-10-31 |
| HUP0100928A2 (hu) | 2001-08-28 |
| BR9908178A (pt) | 2002-01-15 |
| US6197926B1 (en) | 2001-03-06 |
| KR20010041238A (ko) | 2001-05-15 |
| AU2783199A (en) | 1999-09-06 |
| AP2000001888A0 (en) | 2000-09-30 |
| ID26788A (id) | 2001-02-08 |
| CN1294597A (zh) | 2001-05-09 |
| NZ506447A (en) | 2002-11-26 |
| AU741037B2 (en) | 2001-11-22 |
| PL342517A1 (en) | 2001-06-18 |
| EP1056776A1 (en) | 2000-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6197926B1 (en) | Methods for treatment of diabetes using peptide analogues of insulin | |
| EP0246753B1 (en) | Fibroblast growth factor antagonists | |
| CA2182795C (en) | Superactive vip antagonists | |
| JPH10509714A (ja) | ヒトミエリン塩基性タンパク質の９１位におけるペプチドアナログを用いる多発性硬化症の処置方法 | |
| KR102117216B1 (ko) | 강력한 작용제 효과를 지닌 신규한 ｇｈ-ｒｈ 유사체 | |
| JPH10511088A (ja) | 免疫調節活性を有するペプチド | |
| EP0605983A2 (en) | Insulin analogs | |
| AU713067B2 (en) | Cyclic peptide vaccines for treatment and prevention of diabetes | |
| JPH10509460A (ja) | 自己免疫疾患の進行を阻害するための処理方法 | |
| US6562942B1 (en) | Methods for treatment of diabetes using peptide analogues of insulin | |
| JP2002507886A (ja) | アンギオテンシン誘導体 | |
| EP0785947B1 (en) | Peptides endowed with antiinflammatory activity | |
| AU781405B2 (en) | Methods for treatment of diabetes using peptide analogues of insulin | |
| HUP0000836A2 (hu) | Kollagén II-re specifikus T-sejt epitópot tartalmazó peptidek | |
| MXPA00008268A (en) | Methods for treatment of diabetes using peptide analogues of insulin | |
| CZ20003065A3 (cs) | Peptidové analogy insulinu a jejich využití pro léčení diabetes mellitus | |
| US5945401A (en) | Peptide analogues of the 65KD isoform of human glutamic acid decarboxylase and uses thereof | |
| WO1994026292A1 (en) | Amylin antagonists and agonists | |
| EP0519750A2 (en) | Insulin analogs | |
| KR102204476B1 (ko) | 다발성 경화증 치료 및 예방용 조성물 | |
| AU1495700A (en) | Methods for treatment and prevention of diabetes | |
| HK1110352A (en) | Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (iddm) | |
| CA2566828A1 (en) | Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (iddm) |